Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.
Domain Therapeutics applies a multi-string corporate strategy to grow its business through:
Prexton Therapeutics closes a series B ($31M) to progress Foliglurax in phase II
Domain Therapeutics and Merck enter into a license and collaboration agreement for development of adenosine receptor antagonists in immuno-oncology
Domain Therapeutics will attend the AACR Conference on April 1-5 2017 in Washington, USA.
Domain Therapeutics grants Alkermes a non-exclusive license for its G Protein-Coupled Receptor BioSens-All™ technology